ENTR-601-44

N/A

Report date: 2026/05/07 20:00:36

NME

Base Information

Drug NameENTR-601-44

Drug Alias NameExon 44 Skipping Oligonucleotide (Entrada Therapeutics)ENTR60144

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Peptide-oligonucleotide ConjugateSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC) > Peptide-oligonucleotide Conjugate

Mechanisms of ActionRNA modulators

TargetsRibonucleic Acid

Therapy Area/IndicationsMuscular Dystrophy, Duchenne

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesItaly +[5]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesEntrada Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesEntrada Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMuscular Dystrophy, Duchenne

Inactive IndicationsN/A

Other Information

ATC CodeN/A